Parathyroid Hormone (Parathormone)

A polypeptide hormone (84 amino acid residues) secreted by the PARATHYROID GLANDS which performs the essential role of maintaining intracellular CALCIUM levels in the body. Parathyroid hormone increases intracellular calcium by promoting the release of CALCIUM from BONE, increases the intestinal absorption of calcium, increases the renal tubular reabsorption of calcium, and increases the renal excretion of phosphates.

Also Known As:

Networked: 8224 relevant articles (175 outcomes, 699 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Fukagawa, Masafumi: 44 articles (06/2015 - 03/2002)
2.	Bilezikian, John P: 38 articles (01/2015 - 05/2002)
3.	Chen, Herbert: 22 articles (01/2016 - 08/2002)
4.	Jüppner, Harald: 22 articles (10/2015 - 11/2002)
5.	Inaba, Masaaki: 21 articles (03/2015 - 06/2002)
6.	Goodman, William G: 20 articles (07/2015 - 04/2002)
7.	Komaba, Hirotaka: 19 articles (06/2014 - 08/2008)
8.	Sugimoto, Toshitsugu: 19 articles (01/2014 - 12/2002)
9.	Moe, Sharon M: 18 articles (07/2015 - 01/2003)
10.	Cozzolino, Mario: 18 articles (06/2015 - 10/2002)

Related Diseases

1.	Osteoporosis 01/01/2012 - "Intermittent administration of parathyroid hormone (PTH) dramatically increases bone mass and currently is one of the most effective treatments for osteoporosis. " 05/01/2006 - "Clinical data suggested that parathyroid hormone (PTH) might be effective in improving bone mass in patients with osteoporosis, providing its resorptive effects, which are particularly marked at cortical sites, were kept under control. " 07/01/2010 - "Parathyroid hormone (PTH) is the first bone anabolic drug approved for the treatment of osteoporosis, and intriguingly a number of animal studies suggest that PTH could be beneficial in the treatment of fractures and could thus be a potentially new treatment option for induction of fracture healing in humans. " 08/31/2006 - "Parathyroid hormone in the recommended dose of 20 g daily has proved to be a safe and effective drug, stimulating the reconstruction of structurally damaged bone and significantly decreasing fracture risk in patients with severe osteoporosis." 11/01/2011 - "Many studies have shown that parathyroid hormone (PTH), an anabolic agent targeting bone, is effective in reversing bone loss caused by osteoporosis with negative bone remodeling in clinical studies. "
2.	Hypercalcemia (Milk Alkali Syndrome) 10/01/2007 - "These anabolic effects occurred in association with hypercalcemia and were significantly greater than those achievable with high concentrations of daily PTH(1-34). " 07/01/2004 - "Is there enough evidence that evening dosing is more beneficial with respect to suppression of parathyroid hormone and reduction of side effects such as hypercalcemia?" 05/01/1994 - "Inactivation by plasma may be responsible for lack of efficacy of parathyroid hormone antagonists in hypercalcemia of malignancy." 08/01/1988 - "Improved differential diagnosis of hypercalcemia by hypocalcemic stimulation of parathyroid hormone secretion." 01/01/1992 - "In the present study, a possible involvement of parathyroid hormone (PTH) in the development of hypercalcemia in rat was studied by using a newly-developed sensitive and specific radioimmunoassay system for the determination of rat PTH. "
3.	Secondary Hyperparathyroidism 09/01/2003 - "A high level of parathyroid hormone (PTH) is considered to be an indicator of poor prognosis and a poor quality of life of dialysis patients; therefore, an effective and safe therapy for secondary hyperparathyroidism (SHPT) has been developed. " 06/01/2003 - "Data on potential benefits, including improved histologic abnormalities of bone from secondary hyperparathyroidism, increased bone mineral density, and a reduction of elevated parathyroid hormone levels, are documented. " 03/01/2002 - "Secondary hyperparathyroidism decreases renal clearance of parathyroid hormone (PTH). " 07/01/2015 - "The study aimed to evaluate the diagnostic accuracy of intraoperative intact parathyroid hormone (IO-iPTH) in patients with secondary hyperparathyroidism (HPT). " 01/07/2015 - "Using data from the international Dialysis Outcomes and Practice Patterns Study, trends in parathyroid hormone levels and secondary hyperparathyroidism therapies over the past 15 years and the associations between parathyroid hormone and clinical outcomes are reported; 35,655 participants from the Dialysis Outcomes and Practice Patterns Study phases 1-4 (1996-2011) were included. "
4.	Hyperparathyroidism 01/01/2002 - "During the last five years, minimally invasive procedures have been adopted for the surgical treatment of hyperparathyroidism, because preoperative localization studies such as high-resolution ultrasonography and sestamibi scintigraphy, guidance by intraoperative scans, and the use of quick, intraoperative parathyroid hormone assay have improved. " 09/01/2011 - "Intraoperative parathyroid hormone (IoPTH) testing is useful in the management of hyperparathyroidism. " 08/01/1995 - "Comparing the drop in intact parathormone levels between cured patients and those with persistent hyperparathyroidism after surgery showed statistically significant differences. " 08/01/1984 - "These results demonstrate usefulness of homologous radioimmunoassay for human PTH(1-34) in diagnosis and management of hyperparathyroidism, as well as in studying the clearance of amino-terminal portion of PTH which is known to represent biological activity." 01/01/1983 - "Parathormone assay remains the "gold standard" for definitive diagnosis of hyperparathyroidism."
5.	Primary Hyperparathyroidism 02/25/1995 - "To evaluate the efficacy of rapid peroperative assay of parathormone in patients with primary hyperparathyroidism compared with the longer standard assay. " 12/01/2007 - "Measurement of qPTH (based solely on the criterion of greater than 50% decline of parathyroid hormone) in 72 patients with primary hyperparathyroidism (77 procedures) showed true-positive results in 69, false-positive results in 4, and true-negative results in 4 procedures. " 02/01/2009 - "The aim of our study was to evaluate the efficacy of Tc(99m) sestamibi preoperative imaging, intraoperative Tc(99m) sestamibi with gamma probe, and intraoperative parathyroid hormone (IOPTH) assessment in a large cohort of patients with primary hyperparathyroidism. " 10/01/2003 - "We conclude that the PTH (1-84)-IRMA offers improved diagnostic sensitivity in patients with primary hyperparathyroidism than other currently available assays. " 03/01/1989 - "The recent introduction of improved radioimmunoassays for measurement of circulating parathyroid hormone has led to greatly improved sensitivity of this test for the diagnosis of primary hyperparathyroidism. "

Related Drugs and Biologics

1.	Calcium
2.	Phosphorus
3.	Calcitriol (Calcijex)
4.	Vitamin D
5.	cinacalcet (Sensipar)
6.	hydroxide ion
7.	Alkaline Phosphatase
8.	Teriparatide (Parathar)
9.	Diphosphonates
10.	Cholecalciferol (Vitamin D3)

Related Therapies and Procedures

1.	Parathyroidectomy
2.	Renal Dialysis (Hemodialysis)
3.	Thyroidectomy
4.	Aftercare (After-Treatment)
5.	Subcutaneous Injections